Standard BioTools Inc. filings document the regulatory record for a life-science research tools company centered on mass cytometry, microfluidics, genomics, single-cell proteomics and spatial proteomics. Current reports cover operating results, revenue outlook disclosures, restructuring and cost-savings actions, capital-structure changes, material agreements and risk factors tied to its research-use instrument, consumable and service portfolio.
Proxy materials describe board elections, executive compensation votes, auditor ratification, equity incentive plan approvals and employee stock purchase plan amendments. Form 8-K filings also record material events such as the completed SomaLogic sale, related financial disclosures, shareholder voting matters and Nasdaq continued-listing compliance notices.
Standard BioTools (LAB) entered into an agreement under which Element Biosystems, LLC, an acquisition vehicle formed by GMT Venture, will acquire its mass cytometry business for $5.5 million in cash, subject to customary adjustments. The sale requires stockholder approval, completion of the Treeline merger and other customary conditions, and is expected to close by the end of 2026, substantially concurrently with the merger.
Standard BioTools and Multiplex Bio mutually terminated their earlier agreement, and Standard BioTools agreed to pay a $1.5 million termination fee. GMT Venture agreed to pay Multiplex Bio $1.0 million directly or indirectly on Standard BioTools’ behalf toward that fee. Standard BioTools said the Element terms would increase by approximately $15 million the net cash used to calculate the Treeline merger’s final exchange ratio versus Multiplex, after related fees; the comparison also reflects the former agreement’s required $10 million working-capital loan.
The Element agreement has no financing condition. Either party may terminate if the sale is not completed on or before June 30, 2027, subject to up to two automatic three-month extensions in specified circumstances. In specified termination circumstances, Standard BioTools may owe Element a $1.0 million fee and may have to refund GMT Venture’s contribution.
STANDARD BIOTOOLS INC. (LAB) is seeking stockholder approval for an all‑stock merger with Treeline Biosciences, Inc., registering up to 2,101,718,733 shares of its common stock for issuance in the Merger and for resale by Treeline stockholders. The combined company will be renamed Treeline Biosciences Holdings, Inc. and is expected to trade on Nasdaq under the symbol “TRLN.”
The Merger exchange ratio is based on an assumed $2.5 billion equity value for Treeline and $460 million for Standard BioTools, adjusted for Parent Net Cash, implying pro forma ownership of about 84% for former Treeline holders and 16% for current Standard BioTools holders on a fully diluted basis. Standard BioTools will also effect a Charter Amendment to change its name and implement a reverse stock split within a specified ratio range.
Standard BioTools plans to divest its mass cytometry business to Multiplex Bio Inc. under a Share and Asset Purchase Agreement, and use commercially reasonable efforts to monetize its remaining Legacy Businesses. Existing stockholders are expected to receive one contingent value right (CVR) per share, with up to 76,000,000 combined‑company shares potentially issuable over five years from Legacy Businesses monetizations and other specified proceeds. The transaction is structured as a reverse recapitalization with Treeline as the accounting acquirer, so Treeline’s historical financials will become those of the combined company.
STANDARD BIOTOOLS INC. (LAB) reported that executive Sean Mackay, SVP & Chief Business Officer, had 25,729 shares of common stock withheld on August 20, 2026 to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this tax-withholding disposition, he holds 1,480,823 shares of common stock directly.
STANDARD BIOTOOLS INC. (LAB) reported that Chief Financial Officer Hanjoon Alex Kim had 28,195 shares of common stock withheld on August 20, 2026 to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. This was a code F transaction, meaning shares were delivered or withheld for tax payment rather than sold in the open market. After this withholding, Kim directly held 2,534,859 shares of STANDARD BIOTOOLS common stock.
STANDARD BIOTOOLS INC. (LAB) reported that President & CEO Michael Egholm had 97,627 shares of common stock withheld on August 20, 2026 to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this tax-withholding disposition, he directly holds 6,137,704 shares of common stock.
STANDARD BIOTOOLS INC. received an amended Schedule 13G filing from MAK Capital Fund LP, MAK Capital One LLC, and Michael A. Kaufman, reporting a significant ownership position. The reporting persons collectively beneficially own 28,813,904 shares of Common Stock, representing 7.3% of the outstanding class.
This percentage is calculated based on 28,813,904 shares beneficially owned as of June 30, 2026, and 392,578,808 shares outstanding as of August 3, 2026. The reporting persons have 0 shares with sole voting or dispositive power and 28,813,904 shares with shared voting and dispositive power, indicating coordinated control over this stake.
Standard BioTools Inc. has a significant shareholder reporting passive ownership on a Schedule 13G. Long Focus Capital Management, LLC and its controller, John Helmers, report beneficial ownership of 23,500,000 shares of Standard BioTools common stock, representing 6.0% of the class as of June 30, 2026. They hold no sole voting or dispositive power, but have shared voting and shared dispositive power over these shares pursuant to investment management agreements with their clients, on whose behalf the securities were purchased. No single client is said to own more than 5% of the outstanding common stock.
Standard BioTools Inc. reported slightly lower continuing revenue but a sharp swing to profitability for the six months ended June 30, 2026, largely from divesting its SomaScan Business. Continuing operations generated $41.3 million of revenue, down 2% year over year, with gross margin improving to 53%.
Operating expenses from continuing operations fell 20% to $59.7 million as research and development and selling, general and administrative costs were reduced following prior restructuring, although transaction and integration expenses tied to strategic deals rose to $14.7 million. Continuing operations still posted a net loss of $36.2 million. Including discontinued operations, net income reached $100.3 million, driven by a $172.3 million pre-tax gain on the January 2026 sale of the SomaScan Business to Illumina, which provided $388.2 million of net cash. Cash, cash equivalents and restricted cash rose to $272.1 million, with additional short- and long-term investments of $273.0 million and total liabilities of $87.2 million, leaving the company in a strong net cash position.
Strategically, the company agreed to an all-stock merger with Treeline Biosciences expected to close in the second half of 2026, with Treeline treated as the accounting acquirer and existing Standard BioTools stockholders projected to own about 16% of the combined company. Stockholders are expected to receive contingent value rights tied to monetizing the remaining mass cytometry and microfluidics businesses and certain investments. Subsequent to quarter-end, the company arranged a sale of its mass cytometry business for up to $10.0 million of primarily non-cash consideration and secured a $30.0 million cash settlement from Illumina for terminating earnout and royalty arrangements, which is expected to add a further gain in the third quarter of 2026.
Standard BioTools Inc. reported second quarter 2026 revenue of $20.1 million, down 7.6% year-over-year, with product revenue of $14.5 million and services and other revenue of $5.6 million. Gross margin improved to 52.4%, and non-GAAP gross margin reached 56.3%.
Operating expenses were $35.9 million, including $14.7 million of transaction costs and $2.8 million of restructuring charges, resulting in an operating loss of $25.4 million and a net loss from continuing operations of $21.5 million, or $0.06 per share. Adjusted EBITDA loss narrowed to $2.5 million from $16.1 million a year earlier, reflecting a 50% reduction in non-GAAP operating expenses. Cash, cash equivalents, restricted cash, and short- and long-term investments totaled $541.1 million, up from $227.9 million a year earlier, supported by proceeds from a business sale. The company highlighted progress toward a planned merger with Treeline Biosciences, an agreement to sell its Mass Cytometry business, and Illumina’s early buyout of $30 million of contingent payments, and it withdrew its full year 2026 revenue outlook due to the pending merger.
STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported a tax-withholding disposition of 362,625 shares of common stock on August 3, 2026 at $0.868 per share. The shares were withheld to satisfy tax obligations triggered by vesting restricted stock units granted on August 1, 2025. After this transaction, Egholm directly owns 6,235,331 common shares.